您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2022 - 03 - 11
点击次数: 0
所属职位: 首席医学官
所属公司: 上海岸迈生物科技有限公司
个人简介:
彭彬博士毕业于广州中山医科大学获学士和硕士,又获英国纽卡素大学肿瘤临床药理学博士。在英国曼切斯特大学药学院完成博士后学习后, 1998年被瑞士诺华制药公司 (Novartis) 聘任为临床药理部高级研究员. 在此期间, 亲自参与了举世瞩目的第一个抗癌靶向药格列卫 (Glivec) 的研究与开发, 该药的发明导致了抗癌靶向药的划时代的革命.彭彬多次应邀前往 ASCO, AACR, ASH 等大型国际学术会议作格列卫学术报告, 同时也以第一或者合作作者身分在包括NE. Medicine在内的国际重要学术杂志发表了一系列格列卫学术论文. 2009年被美国诺华制药公司肿瘤研发中心聘为全球肿瘤转化医学上海中心执行总监. 领导全球重点为亚太包括中国的早期肿瘤药物的临床研究。2018年加入上海岸迈生物科技有限公司任首席医学官,领导公司双抗的全球临床研发。是北京大学临床研究所客座教授,中国抗癌协会肿瘤药物临床研究专业委员会荣誉委员。拥有极其丰富的国际领导抗肿瘤药物研发的经验。 Dr Bin Peng is currently CMO (Chief Medical Officer)of Shanghai EpimAb Biotherapeutics Co. Ltd. He graduated from Sun Yet-sen University of Medical Sciences in Guangzhou, China. He then earned PhD of Cancer Clinical Pharmacology at Cancer Research Unit, Medical School, University of Newcastle upon Tyne, UK and completed postdoc- fellowship with Dr Malcolm Rowland in Pharmaceutical School, Manchester University, UK . Then he joined Novartis Pharma AG, Basel, Switzerland as senior clinical pharmacologist in 1998. He has been involved in Gleevec (STI571, the first target chemotherapy drug for cancer treatment) entire clinical development from 1998 with the phase I study in man to the registration worldwide in 2001. He joined oncology translational medicine (OTM) department, Novartis as global head of TCO Shanghai in 2009. He is the Guest professor of clinical research institute, Beijing University. In addition, he is an active member of multiple international associations including AACR, ASCO and ASH
发布时间: 2022 - 03 - 11
点击次数: 0
所属职位: 药物化学副总裁
所属公司: 再鼎医药(上海)有限公司
个人简介:
Currently, Dr. Yugui Gu is VP, Medicinal Chemistry at Zai Laboratory. Prior to joining ZaiLab, Yugui was Senior Director of External Research/Chemistry at Cubist Pharmaceuticals, Inc., heading a portfolio of multidisciplinary discovery projects and overseeing exploratory project creation for early discovery pipelines. Yugui worked in Global Pharmaceutical Discovery at Abbott laboratories for 14 years, where he was Senior Group Leader and worked in multiple therapeutic areas. He advanced several development candidates to the clinic. Yugui has 25+ years of drug discovery experience in pharma and biotech with the in-depth knowledge and strong leadership skills in medicinal chemistry and allied fields of drug discovery.  Yugui holds a Ph.D. degree of Organic Chemistry from West Virginia University, Department of Chemistry and a Master of Organic Chemistry from Shanghai Institute of Organic Chemistry.
发布时间: 2022 - 03 - 11
点击次数: 0
所属职位:
所属公司: 长沙通诺信息科技有限公司
个人简介:
李晓晖 博士中南大学湘雅药学院教授、博士生导师,湖湘青年英才,国际肺血管研究院(PVRI)委员,中国药理学会心血管专业委员会常务委员。主要研究领域为心血管药理与临床药理学,主持及参与国家自然科学基金和省市科研项目30项,药物研究项目100余项,发表SCI论文85篇,申请专利37项,获各级奖项31项。Li Xiaohui, Ph.D.l  Professor and Doctoral Tutor of Xiangya School of Pharmaceutical Sciences, Central South Universityl  Research fields: Cardiovascular Pharmacology and Clinical Pharmacology l  Huxiang Young Talentsl  Fellow of the Pulmonary Vascular Research Institute (PVRI)l  Standing Member of the Cardiovascular Professional Committee of the Chinese Pharmacological Societyl  30 government science and technology projectsl  More than 100 drug research programsl  85 SCI papers l  37 patentsl  31 awards
发布时间: 2022 - 03 - 11
点击次数: 0
所属职位: 转化研究总监
所属公司: 上海岸迈生物科技有限公司
个人简介:
董丽琴博士毕业于厦门大学并获得博士学位。之后赴英国学习和工作,过去的18年中,先后学习和任职于英国世界著名研究院所和生物技术制药行业。在供职于牛津大学,伦敦大学学院-CRUK癌症研究所期间,曾主领由CRUK,European framework programme资助的大型科研项目。在回到中国前,任职于阿斯利康 英国,负责癌症基因组科学项目的科学策略制定,及项目的成功交付。她是美国癌症研究协会AACR的活跃会员。并曾参加多个国际科学学术会议,包括AACR, ASCO等。 Dr Liqin Dong is currently the Translational Research Director of Shanghai EpimAb Biotherapeutics Co. Ltd. She leads clinical translational group in EpimAb. She graduated from Xiamen University, China with PhD degree. Then she spent 18 years studying and working in both academia and biotechnology/pharmaceutical industry in United Kingdom. She has experience of leading consortium projects funded by Cancer Research UK, European framework programmes, etc when she worked in University of Oxford, University College London – CRUK Cancer Institute. Her latest role before returning back to China has been in AstraZeneca UK as Genomics Science Delivery Lead, responsible for effective, and successful Oncology genomics portfolio projects delivery. She owns and leads both Scientific Delivery and Scientific Project Management for Oncology genomics portfolio projects including both early and late phase projects, and enables timely projects delivery to Oncology. She is an active associate member of AACR. She has presented her previous research in international conferences, meetings including AACR, ASCO, FP6, FP7 framework programmes.
74页次9/19首页上一页...  45678910111213...下一页尾页
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务